Mechanism-driven innovation is shaping the next chapter of ADC development! In this discussion from ESMO 2025, our Chief Medical Officer Harpreet Singh, MD speaks with Cesar Perez M.D., Director of the Drug Development Unit at the Sarah Cannon Research Institute at Florida Cancer Specialists & Research Institute, about early Phase 1/2 data on CRB-701, a next-generation Nectin-4–targeting ADC. Designed to reduce toxicities seen with MMAE-based ADCs, CRB-701 demonstrated promising response rates, durable disease control, and a manageable safety profile across tumor types, including head and neck and cervical cancers. Watch their discussion here. Corbus Pharmaceuticals

Earlier this month I had the pleasure of speaking with Dr. Cesar Perez M.D., Director of the Drug Development Unit at the Sarah Cannon Research Institute at Florida Cancer Specialists & Research Institute, to discuss the phase 1/2 data on CRB-701, a next-generation Nectin-4–targeting ADC presented at ESMO 2025. CRB-701 is designed to minimize dose-limiting toxicities commonly seen with MMAE-based ADCs, delivering what Dr. Perez described the precision and promise ADCs are known for. The early data are encouraging, demonstrating robust response rates, durable disease control across tumor types, and a manageable safety profile with fewer ocular and neuropathy-related events. It’s exciting to see an ADC candidate showing promising early data across this range of indications, including head and neck squamous cell carcinoma and cervical cancer. We look forward to seeing how this program evolves through dose optimization and maturation of data. Watch the full conversation here to learn more about this promising molecule and what it could mean for the next generation of ADC development. #ESMO2025 #OncologyInnovation #ADCs #DrugDevelopment #HeadandNeck Corbus Pharmaceuticals Precision For Medicine Precision Medicine Group

🔬 Dual Targeting HER2 and PD-1 in Esophagogastric Cancer The phase 2 PHERFLOT trial showed remarkable efficacy by adding pembrolizumab (PD-1 inhibitor) and trastuzumab (HER2 antibody) to standard FLOT chemotherapy, achieving a 48.4% pCR rate in HER2+ esophagogastric adenocarcinoma. To support studies on these emerging pathways, Genomeditech offers validated HER2 and PD-1 cell lines for drug discovery and translational research. Explore more:  HER2👉 https://lnkd.in/gZnzw8kb PD-1👉 https://lnkd.in/gfVj-Eze 🎁 Don’t miss our Thanksgiving & Black Friday Sale! Enjoy up to 35% off on Overexpression & Reporter Cell Lines from Nov. 24th – Dec. 7th. Know more at 👉https://lnkd.in/gH3uys9K #HER2 #PD1 #Immunotherapy #CancerResearch #Genomeditech

A great example of how dual targeting strategies are reshaping oncology. HER2 and PD-1 remain two of the most dynamic pathways in cancer research.

📌FDA has officially approved GSK’s Blenrep for relapsed or refractory multiple myeloma. This marks a significant milestone in our fight against one of the world’s most common blood cancers. ✨ Blenrep has shown a 51% reduction in death risk and has tripled progression-free survival in trials....a remarkable step forward for patients and clinicians. As someone working in pharma, it’s inspiring to see years of research and collaboration delivering hope to those who need it most. Major credit to the teams dedicated to pushing boundaries and turning challenges into breakthroughs. Multiple myeloma is the third most common blood cancer, and approvals like this are what drive our industry forward.

Thanks to both Cancer Therapy Advisor and Life Sciences Review for their recent features highlighting us at Dewpoint Therapeutics. The Cancer Therapy Advisor piece highlights the FDA’s recent Orphan Drug Designation for DPTX3186, our first-in-class condensate modulator targeting Wnt/β-catenin in gastric cancer—a milestone that marks the entry of condensate-modulating therapeutics into the clinic. https://lnkd.in/eCRqekS4 Meanwhile, Life Sciences Review named Dewpoint one of its “Integrated Drug Discovery Platform Companies of the Year,” recognizing how our platform combines condensate biology, human genetics, and AI to discover and develop a new generation of medicines. https://lnkd.in/eNUiGCqC Proud of the team advancing this vision from concept to clinic, and grateful to our partners and collaborators who share our belief that condensate science can change the face of medicine.

Medicenna (TSX: MDNA | OTCQX: MDNAF) Reports Q2 FY2026 Financial Results and Corporate Update Here are the key highlights from our second quarter: - Strong Financial Position: Cash runway extended into at least mid-calendar 2026. - MDNA11 Clinical Milestones: Updated data from the ABILITY-1 study will be presented at the ESMO - European Society for Medical Oncology Congress on December 10, 2025. - NEO-CYT Trial Initiation: New neoadjuvant trial in earlier-stage melanoma set to begin in H1 2026 in collaboration with Fondazione Melanoma. - MDNA113 Progression: Our PD-1 × IL-2 bispecific Superkine continues advancing toward IND-enabling studies, with plans for a first-in-human trial in 2026. - Bizaxofusp (MDNA55): Partnership discussions continue for this Phase-3-ready IL-4 Empowered Superkine program. 👉 Read the full news release: https://lnkd.in/gqQ_fGkQ #Medicenna #Superkines #Biotech #Immunotherapy #Oncology #ClinicalTrials #LifeSciences #InvestorRelations

We’re proud to announce the acquisition of our portfolio company ImCheck Therapeutics by Ipsen for a total potential consideration up to €1B.   This acquisition follows robust clinical results in the treatment of acute myeloid leukemia (AML), validating the potential of ICT01 — ImCheck’s first-in-class monoclonal antibody targeting BTN3A, a key immune checkpoint molecule broadly expressed across cancers.   🔗 https://lnkd.in/d6ncQ9TY   Nicolas Dufourcq, Paul-François Fournier, Maïlys Ferrere, Laurent Arthaud, Laurent Higueret, Thibaut Roulon   #Biotech #Innovation #Exit

Innate Pharma got a "Buy" rating & $8 target. Its cancer drug IPH4502 targets a huge $1.5 billion bladder cancer market. https://lnkd.in/d_uBhx5q

🌟Excited to share our recent work presented at #ESMO25 in Berlin🌟   Nordic Market Access’s Therese Dibbern and Peter Carlqvist have co-authored the real-world evidence study “Stage III and IV Malignant Melanoma in Sweden: A Nationwide Study on Health Care Resource Utilization, Productivity Loss and Associated Cost, Prescription Drug Use and Survival Prognosis” featured at the ESMO Congress 2025 in Berlin. 💡 In summary: The study shows that stage III and IV melanoma place a significant burden on the Swedish healthcare system and causes productivity loss, in particular for individuals with distant recurrent malignat melanoma. 🔗 View the abstract and poster here: 👉https://lnkd.in/dXqdpMSj #ESMO2025 #Oncology #Melanoma #HealthEconomics #RealWorldEvidence #NordicMarketAccess